TY - JOUR TT - Pharmacovigilance Screening for Antibacterial Drugs in Commercial and Breeding Broiler Enterprises in Bolu Province AU - Ekici, Hüsamettin AU - Dakman, Asiye AU - Ekici, Seda AU - Çoşar, Mustafa AU - Güleç, Metin PY - 2015 DA - April Y2 - 2015 JF - Erciyes Üniversitesi Veteriner Fakültesi Dergisi JO - Erciyes Üniv Vet Fak Derg PB - Erciyes Üniversitesi WT - DergiPark SN - 1304-7280 SP - 25 EP - 30 VL - 12 IS - 1 KW - Antibakteriyel ilaç KW - broiler KW - farmakovijilans N2 - Pharmacovigilance survey prepared in this study included the incidence of bacterial diseases, status ofperforming antibiogram before using the antibacterial drugs and responsiveness to treatment with theirpharmacovigilance notification as well as some questions were asked. Forms created for this purpose were delivereddirectly to 110 veterinarian working in commercial broiler enterprises (10 enterprises), and to 14 veterinarian working inbreeding broiler enterprises (4 enterprises) in Bolu Province. According to the survey results, 92.8% (13 enterprises) ofbusinesses in the last year experienced diseases of bacterial origin; and 70.16% (87/124) of cases with diseases usedantibacterial drug without antibiyogram. Those using drug without antibiogram received a response from approximately58.6%. Veterinarian working in commercial broiler enterprises emphasis applicability in drug selection has been foundand Veterinarian working in breeding broiler enterprises emphasis easy access in drug selection has been found CR - 1. Akıcı A, Oktay S. Rational pharmacotherapy and pharmacovigilance. Curr Drug Saf 2007; 2(1): 65-9. CR - 2. Aydınkarahaliloğlu D. Beşeri tıbbi ürünlerin güvenliğinin izlenmesi ve değerlendirilmesi hakkında yönetmelik, beşeri tıbbi ürün ruhsatı sahipleri için farmakovijilans kılavuzu neler getiriyor? IKU 2006; 14: 11-5. CR - 3. Doğan F. Veteriner Hekimliğinde Farmakovijilans Taraması. Doktora Tezi. Selçuk Üniv. Sağlık Bilimleri Enstitüsü, Farmakoloji ve Toksikoloji Programı. Konya-Türkiye, 2009. CR - 4. Ekici H, Yarsan E. Effect of different conservation conditions on the active compounds and pharmacovigilance screening of different florfenicol preparations. Kafkas Univ Vet Fak Derg 2013; 19(2): 277-81. CR - 5. EMA. Public bulletin-Veterinary pharmacovigilance 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/03/WC500102583.pdf; Erişim Tarihi: 17.08.2013. CR - 6. European Commission. Amendment Of Commission Regulation (Ec) No 658/2007 Concerning financial penalties for infringements committed by marketing authorisation holders of centrally authorised medicinal products. http://ec.europa.eu/health/documents/latest_news/publ_consult_2011_03_10.pdf; Erişim Tarihi: 10.08.2013. CR - 7. Farmakovijilans Derneği. Farmakovijilans Denetim Kılavuzu. http://www.farmakovijilansdernegi.org/icerik.php?id=53; Erişim Tarihi: 10.08.2013 CR - 8. Frana TS, Elsken LA, Karli SA. Summary of adverse event reports for veterinary biologic products received by the USDA from 1999 through 2005. JAVMA 2006; 229(7): 1100-2. CR - 9. Giguere S. Tetracyclines and glycylcylines. Giguere S. Prescott J. Baggot JD. Walker RD. Dowling PM. eds. In: Antimicrobial Therapy. UK: Blackwell, 2006; pp. 204-31. CR - 10. Giguere S. Macrolides, azalides, and ketolies. Giguere S. Prescott J. Baggot JD. Walker RD. Dowling PM. eds. In: Antimicrobial Therapy, UK: Blackwell, 2006; pp. 191-240, CR - 11. Gross U. Treatment of microsporidiosis including albendazole. Parasitol 2003; 90(1): 14-8. CR - 12. İskit AB. İlaçlarla yapılan gözlemsel (farmakoepidemiyolojik) çalışmalar kılavuzu. İKU Dergisi 2008; 20: 25-33. CR - 13. Müntener CR, Gassner B, Demuth DC, Althaus FR, Zwahlen R. Pharmacovigilance for veterinary drugs in Switzerland. Schweiz Arch Tierh 2004; 146(11): 499-505. CR - 14. Müntener CR, Bruckner L, Gassner B, Demuth DC, Althaus FR, Zwahlen R. Reported adverse reactions of veterinary drugs and vaccines in 2005. Schweiz Arch Tierh 2007; 149(2): 57-63. CR - 15. Naidoo V, Sykes R. Overview of suspected adverse reactions to veterinary medicinal products reported in South Africa (March 2003 - February 2004). J S Afr Vet Assoc 2005; 76(1): 49-52. CR - 16. Resmi Gazete. Beşeri tıbbi ürünlerin güvenliğinin izlenmesi ve değerlendirilmesi hakkında yönetmelik.http://www.resmigazete.gov.tr/main.aspx?home=http://www.resmigazete.gov.tr/eskiler/2005/03/20050322.htm&main=http://www.resmigazete.gov.tr/eskiler/2005/03/20050322.htm; Erişim Tarihi: 10.08.2013. CR - 17. WHO 2002. Safety Monitoring of medicinal products: The importance of pharmacovigilance. http://apps.who.int/medicinedocs/en/d/Js4893e/; Erişim Tarihi: 17.06.2013. CR - 18. WHO 2000. Safety Monitoring of medicinal products: guidelines for setting up and running a Pharmacovigilance Centre. http://apps. who. int/ medicine docs/ en/d/Jh2934e/4.html; Erişim tarihi: 03.02 2013. CR - 19. Tjalve H. Adverse reactions to veterinary drugs reported in Sweden during 1991-1995. Vet Pharmacol Therap 1997; 20(2): 105-10. CR - 20. Woodward KN. Veterinary pharmacovigilance. Part 4. adverse reactions in humans to veterinary medicinal products. J Vet Pharmacol Therap 2005; 28(2): 185-201. CR - 21. Woodward KN. Veterinary pharmacovigilance. Part 6. predictability of adverse reactions in animals from laboratory toxicology studies. J Vet Pharmacol Therap 2005; 28(2): 213-31. CR - 22. Woodward KN. Veterinary pharmacovigilance: adverse Reactions to Veterinary Medical Products. First Edition. United Kingdom: A John Wiley & Sons, 2009; p.755. UR - https://dergipark.org.tr/tr/pub/ercivet/article/281621 L1 - https://dergipark.org.tr/tr/download/article-file/263302 ER -